References
- Fowler VG, Jr., Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med. 2003;163(17):2066–2072. doi:10.1001/archinte.163.17.2066.
- Khatib R, Johnson LB, Fakih MG, et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis. 2006;38(1):7–14. doi:10.1080/00365540500372846.
- Kuehl R, Morata L, Boeing C, et al. Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study. Lancet Infect Dis. 2020;20(12):1409–1417. doi:10.1016/S1473-3099(20)30447-3.
- de Jong NWM, van Kessel KPM, van Strijp JAG. Immune evasion by Staphylococcus aureus. Microbiol Spectr. 2019;7(2) doi:10.1128/microbiolspec.GPP3-0061-2019.
- Souli M, Ruffin F, Choi SH, et al. Changing characteristics of Staphylococcus aureus bacteremia: results from a 21-Year, prospective, longitudinal study. Clin Infect Dis. 2019;69(11):1868–1877. doi:10.1093/cid/ciz112.
- Kimmig A, Hagel S, Weis S, et al. Management of Staphylococcus aureus bloodstream infections. Front Med (Lausanne). 2020;7:616524. doi:10.3389/fmed.2020.616524.
- Yahav D, Franceschini E, Koppel F, et al. Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial. Clin Infect Dis. 2019;69(7):1091–1098. doi:10.1093/cid/ciy1054.
- Molina J, Montero-Mateos E, Praena-Segovia J, et al. Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by enterobacterales: a randomized, controlled trial. Clin Microbiol Infect. 2022;28(4):550–557. doi:10.1016/j.cmi.2021.09.001.
- Thaden JT, Cantrell S, Dagher M, et al. Association of follow-up blood cultures with mortality in patients with Gram-Negative bloodstream infections: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(9):e2232576. doi:10.1001/jamanetworkopen.2022.32576.
- Gatti M, Bonazzetti C, Tazza B, et al. Impact on clinical outcome of follow-up blood cultures and risk factors for persistent bacteraemia in patients with gram-negative bloodstream infections: a systematic review with meta-analysis. Clin Microbiol Infect. 2023;29(9):1150–1158. doi:10.1016/j.cmi.2023.02.024.
- Gunsolus IL, Sweeney TE, Liesenfeld O, et al. Diagnosing and managing sepsis by probing the host response to infection: advances, opportunities, and challenges. J Clin Microbiol. 2019;57(7):e00425-19. doi:10.1128/JCM.00425-19.
- Turgman O, Schinkel M, Wiersinga WJ. Host response biomarkers for sepsis in the emergency room. Crit Care. 2023;27(1):97. doi:10.1186/s13054-023-04367-z.
- U.S. Food and Drug Administration. 510(k) Substantial equivalence determination decision summary SeptiCyte RAPID 2021 Available from: https://www.accessdata.fda.gov/cdrh_docs/reviews/K203748.pdf.
- Brandon R, Kirk J, Yager T, et al. Clinical performance of a rapid sepsis test on a near-patient molecular testing platform 40th International Symposium on Intensive Care & Emergency Medicine (ISICEM); Brussels 2020.
- Miller RR, 3rd, Lopansri BK, Burke JP, et al. Validation of a host response assay, SeptiCyte LAB, for discriminating sepsis from systemic inflammatory response syndrome in the ICU. Am J Respir Crit Care Med. 2018;198(7):903–913. doi:10.1164/rccm.201712-2472OC.
- Verboom DM, Koster-Brouwer ME, Varkila MRJ, et al. Profile of the SeptiCyte LAB gene expression assay to diagnose infection in critically ill patients. Expert Rev Mol Diagn. 2019;19(2):95–108. doi:10.1080/14737159.2019.1567333.
- Montero MM, Hardy-Werbin M, Gonzalez-Gallardo S, et al. Evaluation of the host immune response assay SeptiCyte RAPID for potential triage of COVID-19 patients. Sci Rep. 2023;13(1):944. doi:10.1038/s41598-023-28178-y.
- Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American college of chest physicians/society of critical care medicine. Chest. 1992;101(6):1644–1655. doi:10.1378/chest.101.6.1644.
- StataCorp. 2021. Stata statistical software: release 17. College Station, TX: stataCorp LLC.
- Tomlinson KL, Riquelme SA, Baskota SU, et al. Staphylococcus aureus stimulates neutrophil itaconate production that suppresses the oxidative burst. Cell Rep. 2023;42(2):112064. doi:10.1016/j.celrep.2023.112064.
- Pidwill GR, Gibson JF, Cole J, et al. The role of macrophages in Staphylococcus aureus infection. Front Immunol. 2020;11:620339. doi:10.3389/fimmu.2020.620339.
- Wiggers JB, Xiong W, Daneman N. Sending repeat cultures: is there a role in the management of bacteremic episodes? (SCRIBE study). BMC Infect Dis. 2016;16(1):286. doi:10.1186/s12879-016-1622-z.
- Turjeman A, von Dach E, Molina J, et al. Duration of antibiotic treatment for gram-negative bacteremia - Systematic review and individual participant data (IPD) meta-analysis. EClinicalMedicine. 2023;55:101750. doi:10.1016/j.eclinm.2022.101750.
- Amipara R, Winders HR, Justo JA, et al. Impact of follow up blood cultures on outcomes of patients with community-onset gram-negative bloodstream infection. EClinicalMedicine. 2021;34:100811. doi:10.1016/j.eclinm.2021.100811.
- Chiang HY, Chen TC, Lin CC, et al. Trend and predictors of short-term mortality of adult bacteremia at emergency departments: a 14-Year cohort study of 14 625 patients. Open Forum Infect Dis. 2021;8(11):ofab485. doi:10.1093/ofid/ofab485.